"Neurofibromin 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A membrane protein homologous to the ERM (Ezrin-Radixin-Moesin) family of cytoskeleton-associated proteins which regulate physical properties of membranes. Alterations in neurofibromin 2 are the cause of NEUROFIBROMATOSIS 2.
| Descriptor ID |
D025581
|
| MeSH Number(s) |
D12.776.543.685 D12.776.624.776.612
|
| Concept/Terms |
Neurofibromin 2- Neurofibromin 2
- Moesin-Ezrin-Radixin-Like Protein
- Moesin Ezrin Radixin Like Protein
- Schwannomin Protein
- Protein, Schwannomin
- Neurofibromatosis Type 2 Protein
- NF2 Gene Product
- Gene Product, NF2
- Schwannomin
- Merlin
- Neurofibromatosis 2 Gene Product
|
Below are MeSH descriptors whose meaning is more general than "Neurofibromin 2".
Below are MeSH descriptors whose meaning is more specific than "Neurofibromin 2".
This graph shows the total number of publications written about "Neurofibromin 2" by people in this website by year, and whether "Neurofibromin 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 5 | 0 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 1 | 3 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurofibromin 2" by people in Profiles.
-
Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Neuro Oncol. 2023 03 14; 25(3):520-530.
-
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 09; 129(9):974-985.
-
Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma. Sci Rep. 2020 03 06; 10(1):4211.
-
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Sci Rep. 2020 01 20; 10(1):701.
-
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clin Cancer Res. 2020 01 01; 26(1):242-255.
-
Recurrent Genomic Alterations in Soft Tissue Perineuriomas. Am J Surg Pathol. 2018 12; 42(12):1708-1714.
-
The ERM family member Merlin is required for endometrial gland morphogenesis. Dev Biol. 2018 10 15; 442(2):301-314.
-
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. Mol Cancer Ther. 2017 08; 16(8):1693-1704.
-
NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors. Acta Neuropathol Commun. 2016 05 27; 4(1):55.
-
Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/?-Catenin Signaling. Cancer Res. 2015 Nov 15; 75(22):4778-4789.